My group works on developing novel approaches to improve efficacy and safety of allogeneic stem cell transplantation and adoptive immunotherapy as treatments for blood cancers. We focus on T-cell alloreactivity in the context of stem cell transplantation and immunotherapy.
Our goal is to identify mechanisms that support haematopoietic stem cell function and understand how the leukaemic stem cells “play” with these mechanisms to thrive.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
The central aim of our laboratory is to understand the biology of leukaemic stem cells and identify therapeutic targets to specifically eradicate them, thus discovering novel and efficient leukaemia therapies. We also focus on understanding haematopoietic stem cell biology with the hope to harness this knowledge for expanding them for therapeutic purposes.
Our main research areas are focused on understanding the evolution of Barrett’s oesophagus to cancer, field cancerisation of the human stomach, and clonal expansion in ductal carcinoma in situ of the human breast.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin’s lymphomas in order to define clinically-relevant biomarkers.
We are interested in understanding the cellular and molecular mechanisms responsible for relapses in acute lymphoblastic leukaemia and progressing these insights into translational diagnostics and clinical trials.
The aim of my research project is to identify and functionally characterise candidate disease genes in familial leukaemia.
My research investigates the functional relevance of RNA-binding proteins (RBPS) in normal haematopoiesis and acute myeloid leukaemia (AML) pathogenesis.
My research is focused on investigating how the epitranscriptome regulates normal and malignant haematopoiesis.
I investigate mathematical properties of somatic evolution in the context of both cancerous and healthy tissue.
Our research is focused in defining the cellular interactome of haematopoietic stem cells and leukaemic stem cells inside their niches during adulthood, ageing and disease. We are also interested in the cellular and molecular mechanisms that drive clonal selection and evolution in clonal haematopoiesis.
I am studying how the tumour suppressor gene LIMD1 functions in the microRNA pathway, a gene regulatory pathway that is often dysregulated in cancer.